Press ReleasesFollow CatalYm’s journey and learn more about our most recent milestones December 14, 2022 CatalYm Expands Visugromab Development Based on Positive Early Phase 2 Data in Two Indications and Adds Confirmatory Response-Predictive Biomarker Cohort - Read More November 22, 2022 CatalYm Closes EUR 50 Million Series C Financing to Expand and Accelerate Phase 2 Clinical Development of Visugromab in Patients with Solid Tumors - Read More September 26, 2022 CatalYm Receives FDA IND Clearance to Expand Development of Visugromab in Advanced Cancer Patients into the US - Read More Load MoreLoadingMeet us at the following conferences & events J.P. Morgan '23 January 9-12, 2023 San Francisco, CA, USA Read More BioEurope Spring '23 March 20-22, 2023 Basel, Switzerland Read More AACR '23 April 13-19, 2023 Orlando, FL, USA Read More ASCO '23 June 2-6, 2023 Chicago, IL, USA Read More BIO '23 June 5-9, 2023 Boston, MA, USA Read More
